At Mycovia, we are passionate about developing novel drugs in areas of unmet medical need, with an initial focus in women’s health.
Our lead product candidate, oteseconazole (VT-1161), is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a debilitating chronic condition that affects 138 million women worldwide. Commonly known as a chronic yeast infection, RVVC can severely impact a woman’s physical and emotional well being, and results in billions of dollars in lost productivity.
With no FDA-approved treatments for RVVC in the U.S., there are limited treatment options available for women who experience three or more yeast infections a year. Mycovia has enrolled three Phase 3 clinical studies being conducted to evaluate oteseconazole for the treatment of RVVC and is on path to be the first FDA-approved treatment for this debilitating disease.
Our lead product candidate, oteseconazole (VT-1161), is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a debilitating chronic condition that affects 138 million women worldwide. Commonly known as a chronic yeast infection, RVVC can severely impact a woman’s physical and emotional well being, and results in billions of dollars in lost productivity.
With no FDA-approved treatments for RVVC in the U.S., there are limited treatment options available for women who experience three or more yeast infections a year. Mycovia has enrolled three Phase 3 clinical studies being conducted to evaluate oteseconazole for the treatment of RVVC and is on path to be the first FDA-approved treatment for this debilitating disease.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Reproductive/Sexual Health
Lead Product in Development:
Oteseconazole (VT-1161)
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
